Company news
Recce Pharmaceuticals Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Positive Oral Data on New RECCE 435 Against H. pylori
August 4, 2020
US Researchers to Test RECCE in Expanded SARS-CoV-2 Program
July 16, 2020
RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program
July 8, 2020
Response to ASX Price and Volume Query
May 27, 2020
Positive Data on RECCE 327 Against Neisseria gonorrhoeae
May 4, 2020
Further Positive Data on RECCE 327 Against MRSA Superbug
April 23, 2020
Positive Data on RECCE 327 Against Influenza A
April 20, 2020
Recce Signs Phase I Human Clinical Trial Agreement
April 8, 2020
First-in-Human Clinical Trial Progress Update
March 16, 2020
Half Yearly Report and Accounts
February 27, 2020
Positive Efficacy Data in Kidney/UTI infections animal model
February 13, 2020
Positive Data from RECCE 327 Antibiotic Safety Studies
February 9, 2020
Appendix 4C and Commentary
January 31, 2020
Positive Data for RECCE 327 in MRSA Burns Wound Infection
November 26, 2019
Recce Completes Raising of $6.76 million
October 9, 2019
Key Family 2 Patent Granted in Japan for RECCE Antibiotics
September 20, 2019
Funding Update
September 11, 2019
Appendix 4E - Preliminary Final Report
August 30, 2019
FDA Positive Response for Recce Scaled Manufacture & Quality
August 26, 2019
Response to ASX Appendix 4C Query
August 16, 2019
Key Family 2 Patent Granted in Europe for RECCE Antibiotics
August 8, 2019
Opening R&D Address at World Antibiotic Resistance Congress
July 31, 2019
Appendix 4C and commentary
July 30, 2019
Appointment of Independent Chair and Additional Director
July 9, 2019
USA Patent Granted for Recces Antibiotics
March 13, 2019
Recce Successfully Raises $1.8 million via Placement
February 7, 2019
Change of Registry Address: Automic P/L - Sydney Office
September 28, 2018
Key Australian Patent for Recces Broad-Spectrum Antibiotics
July 31, 2018
Update on Progress of Broad Spectrum Antibiotic RECCE 327
July 18, 2018
Update on meeting with US FDA
June 5, 2018
Additional AU$861,590 R&D Tax Incentive Rebate Received
April 22, 2018
Recce Half Yearly Report and Appendix 4D
February 28, 2018
Data Submission & Further Communication Request with US FDA
February 14, 2018
AusIndustry Awards Recce Financial Support
January 14, 2018
US FDA Grants Qualified Infectious Disease Product Designati
November 15, 2017
Appendix 4C - quarterly
October 31, 2017
Recce Launches Share Purchase Plan
September 27, 2017
Response to ASX Price Query
September 18, 2017
Recce Confirms Pre-IND Data Submission to US FDA
September 6, 2017
Appendix 4E and Financial Report
August 31, 2017
Recce Confirms Delivery by Intravenous Drip
July 30, 2017
Recce achieves milestone with volume production
July 19, 2017
Recce constructs automated manufacturing facility to support
June 22, 2017
Recce secures up to A$6.05 million investment agreement with
June 16, 2017
Recce moves closer to clinical study application
May 19, 2017
Operational Update
April 9, 2017
Data from large animal study shows RECCE 327 well tolerated
March 26, 2017
Appendix 4D and Interim Financial Statements
February 28, 2017
Microscopy Images of its Synthetic Antibiotic in Action Dest
February 23, 2017
Recce to suspend anti-cancer program
February 22, 2017
Decks
The 5 newest of 45 decks. Every deck is listed under its year.
- Shareholder Meeting (November 2026)
Shareholder meeting · 19 slides · Nov 6, 2026
- Investor Presentation (November 2026)
Investor deck · 45 slides · November 2026
- Investor Presentation (October 2026)
Investor deck · 42 slides · October 2026
- Shareholder Meeting (September 2026)
Shareholder meeting · 10 slides · Sep 2, 2026
- Investor Presentation (September 2026)
Investor deck · 42 slides · September 2026